(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Marathon, Riot Blockchain, and Immutep Limited.

The three biggest losers today are Akerna Corp., Lazydays Holdings, and LM Funding America.

Winners today

1. Marathon (MARA) – 12.75%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon rising 12.75% to $8.75 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-4.05.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -76.14%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Marathon’s stock is considered to be overbought (>=80).

Revenue Growth

Year-on-year quarterly revenue growth grew by 228%, now sitting on 174M for the twelve trailing months.

Moving Average

Marathon’s worth is way below its 50-day moving average of $10.05 and way below its 200-day moving average of $10.07.

Sales Growth

Marathon’s sales growth is 744.3% for the present quarter and 387.9% for the next.

More news about Marathon.

2. Riot Blockchain (RIOT) – 11.33%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 11.33% to $9.88 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.82%.

Moving Average

Riot Blockchain’s worth is below its 50-day moving average of $10.48 and below its 200-day moving average of $10.49.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 8.3% and 72.2%, respectively.

More news about Riot Blockchain.

3. Immutep Limited (IMMP) – 10.27%

Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as ‘eftilagimod alpha' or ‘efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

NASDAQ ended the session with Immutep Limited jumping 10.27% to $2.04 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 0.27% to $13,018.33, after four sequential sessions in a row of losses, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Immutep Limited has a trailing twelve months EPS of $-0.28.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.61%.

Yearly Top and Bottom Value

Immutep Limited’s stock is valued at $2.04 at 17:32 EST, way under its 52-week high of $3.90 and way higher than its 52-week low of $1.50.

Sales Growth

Immutep Limited’s sales growth is negative 61.6% for the present quarter and negative 61.6% for the next.

More news about Immutep Limited.

4. Seres Therapeutics (MCRB) – 9.51%

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Seres Therapeutics jumping 9.51% to $1.55 on Monday, following the last session’s upward trend. NASDAQ rose 0.27% to $13,018.33, after four consecutive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Seres Therapeutics has a trailing twelve months EPS of $-1.18.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -671.83%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 10300.7%, now sitting on 130.37M for the twelve trailing months.

Volume

Today’s last reported volume for Seres Therapeutics is 7666190 which is 229.91% above its average volume of 2323700.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Seres Therapeutics’s EBITDA is 13.46.

Yearly Top and Bottom Value

Seres Therapeutics’s stock is valued at $1.55 at 17:32 EST, way below its 52-week high of $9.49 and way above its 52-week low of $1.28.

More news about Seres Therapeutics.

5. MicroStrategy (MSTR) – 8.9%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy jumping 8.9% to $379.01 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $9.37.

PE Ratio

MicroStrategy has a trailing twelve months price to earnings ratio of 40.45. Meaning, the purchaser of the share is investing $40.45 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 65.4%.

Volume

Today’s last reported volume for MicroStrategy is 727428 which is 31.88% above its average volume of 551557.

Volatility

MicroStrategy’s last week, last month’s, and last quarter’s current intraday variation average was 1.68%, 0.40%, and 2.43%.

MicroStrategy’s highest amplitude of average volatility was 2.63% (last week), 2.36% (last month), and 2.43% (last quarter).

Moving Average

MicroStrategy’s worth is way higher than its 50-day moving average of $341.14 and way higher than its 200-day moving average of $311.49.

Sales Growth

MicroStrategy’s sales growth is negative 0.6% for the ongoing quarter and 0.6% for the next.

More news about MicroStrategy.

6. Huazhu Group (HTHT) – 8.13%

H World Group Limited, together with its subsidiaries, develops leased and owned, manachised, and franchised hotels primarily in the People's Republic of China. The company operates hotels under its own brands, such as HanTing Hotel, Ni Hao Hotel, Hi Inn, Elan Hotel, Zleep Hotels, Ibis Hotel, JI Hotel, Orange Hotel, Starway Hotel, Ibis Styles Hotel, CitiGO Hotel, Crystal Orange Hotel, IntercityHotel, Manxin Hotel, Mercure Hotel, Madison Hotel, Novotel Hotel, Joya Hotel, Blossom House, Steigenberger Hotels & Resorts, MAXX by Steigenberger, Jaz in the City, Grand Mercure, Steigenberger Icon, and Song Hotels. The company was formerly known as Huazhu Group Limited and changed its name to H World Group Limited in June 2022. The company was founded in 2005 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Huazhu Group jumping 8.13% to $36.85 on Monday, after four sequential sessions in a row of losses. NASDAQ rose 0.27% to $13,018.33, after four sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Huazhu Group has a trailing twelve months EPS of $0.46.

PE Ratio

Huazhu Group has a trailing twelve months price to earnings ratio of 80.11. Meaning, the purchaser of the share is investing $80.11 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.64%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 63.5%, now sitting on 17.81B for the twelve trailing months.

More news about Huazhu Group.

7. LiqTech International (LIQT) – 6.61%

LiqTech International, Inc., a clean technology company, designs, develops, produces, markets, and sells automated filtering systems, ceramic silicon carbide liquid applications, and diesel particulate air filters in the United States, Canada, Europe, Asia, and South America. It operates in three segments: Water, Ceramics, and Plastics. The company manufactures and sells silicon carbide ceramic filtration technologies for liquid and gas purification; and diesel particulate filters for exhaust emission control solutions to the verified retrofit and the original equipment manufacturer market. In addition, it develops, manufactures, and sells liquid filtration systems, which are used for the marine scrubber systems, filtration of produced water, industrial applications, pool and spa water, food and beverage application, and silicon carbide membrane technology. Further, the company manufactures machined and welded plastic parts. LiqTech International, Inc. sells its products primarily to industrial customers through direct sales, systems integrators, distributors, agents, and partners. The company was formerly known as Blue Moose Media, Inc. and changed its name to LiqTech International, Inc. in October 2011. LiqTech International, Inc. was founded in 2000 and is headquartered in Ballerup, Denmark.

NASDAQ ended the session with LiqTech International jumping 6.61% to $3.71 on Monday, following the last session’s upward trend. NASDAQ jumped 0.27% to $13,018.33, after four successive sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, LiqTech International has a trailing twelve months EPS of $-0.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -33.38%.

Volume

Today’s last reported volume for LiqTech International is 8669 which is 32.22% below its average volume of 12790.

Moving Average

LiqTech International’s worth is under its 50-day moving average of $3.72 and above its 200-day moving average of $3.64.

Sales Growth

LiqTech International’s sales growth is 21% for the present quarter and 74.1% for the next.

More news about LiqTech International.

8. MIND Technology (MINDP) – 6.58%

MIND Technology, Inc., together with its subsidiaries, provides technology to the oceanographic, hydrographic, defense, seismic, and maritime security industries. It operates in two segments, Seamap Marine Products and Klein Marine Products. The company's products include the GunLink seismic source acquisition and control systems that provide operators of marine seismic surveys with precise monitoring and control of energy sources; the BuoyLink RGPS tracking system, which is used to offer precise positioning of marine seismic energy sources and streamers; Sleeve Gun energy sources; Sea Serpent line of passive sonar arrays for maritime security and anti-submarine warfare applications; SeaLink towed streamer systems; and SeaLink towed seismic streamer system. It also provides streamer weight collars, depth and pressure transducers, air control valves, and source array systems; spare and replacement parts; and repair and engineering services, training and field service operations, and umbilical terminations, as well as side scan sonar equipment and systems. The company markets its products to governmental and commercial customers through internal sales organization and a network of distributors and representatives. It operates in the United States, Europe, Canada, Africa, Mexico, South America, the Asia/South Pacific, and internationally. The company was formerly known as Mitcham Industries, Inc. MIND Technology, Inc. was incorporated in 1987 and is headquartered in The Woodlands, Texas.

NASDAQ ended the session with MIND Technology rising 6.58% to $12.47 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, MIND Technology has a trailing twelve months EPS of $-1.22.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.53%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Oct 11, 2023, the estimated forward annual dividend rate is 2.25 and the estimated forward annual dividend yield is 19.31%.

Yearly Top and Bottom Value

MIND Technology’s stock is valued at $12.47 at 17:32 EST, way under its 52-week high of $14.00 and way above its 52-week low of $5.15.

Moving Average

MIND Technology’s worth is above its 50-day moving average of $11.72 and way higher than its 200-day moving average of $8.54.

More news about MIND Technology.

9. Coinbase (COIN) – 6.46%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. It offers the primary financial account in the cryptoeconomy for consumers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable developers to build crypto-based applications and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase jumping 6.46% to $79.49 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $-5.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.09%.

Volatility

Coinbase’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.97%, a positive 0.16%, and a positive 2.68%.

Coinbase’s highest amplitude of average volatility was 2.97% (last week), 2.25% (last month), and 2.68% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Coinbase’s stock is considered to be overbought (>=80).

More news about Coinbase.

10. Kodiak Sciences (KOD) – 6.25%

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

NASDAQ ended the session with Kodiak Sciences jumping 6.25% to $1.70 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Kodiak Sciences has a trailing twelve months EPS of $-6.17.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -68.66%.

Moving Average

Kodiak Sciences’s worth is way under its 50-day moving average of $2.10 and way below its 200-day moving average of $5.22.

Yearly Top and Bottom Value

Kodiak Sciences’s stock is valued at $1.70 at 17:32 EST, way under its 52-week high of $9.80 and way higher than its 52-week low of $1.51.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Kodiak Sciences’s EBITDA is -0.34.

Volume

Today’s last reported volume for Kodiak Sciences is 540485 which is 50.05% below its average volume of 1082150.

More news about Kodiak Sciences.

Losers Today

1. Akerna Corp. (KERNW) – -33.19%

NASDAQ ended the session with Akerna Corp. falling 33.19% to $0.02 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Yearly Top and Bottom Value

Akerna Corp.’s stock is valued at $0.02 at 17:32 EST, way above its 52-week high of $0.02.

More news about Akerna Corp..

2. Lazydays Holdings (LAZY) – -25.79%

Lazydays Holdings, Inc. operates recreation vehicle (RV) dealerships under the Lazydays name in the United States. It provides RV sales, RV parts and services, after-market parts and accessories, and RV camping facilities. The company offers various new and used RVs; onsite general RV maintenance and repair services; and collision repair services, as well as sells and installs various parts and accessories, such as tow hitches, satellite dishes, and suspension systems. It also operates the Lazydays RV resort at Tampa, Florida. In addition, the company arranges financing for vehicle purchases through third-party finance sources; and offers various third-party protection insurance plans and services to the purchasers of its RVs. It operates dealerships locations at The Villages, Florida; Tucson, Arizona; Minneapolis, Minnesota; Knoxville, Tennessee; and Loveland and Denver, Colorado. The company was founded in 1976 and is based in Seffner, Florida.

NASDAQ ended the session with Lazydays Holdings dropping 25.79% to $6.10 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Lazydays Holdings has a trailing twelve months EPS of $0.29.

PE Ratio

Lazydays Holdings has a trailing twelve months price to earnings ratio of 21.03. Meaning, the purchaser of the share is investing $21.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.12%.

Sales Growth

Lazydays Holdings’s sales growth is negative 4.9% for the ongoing quarter and 3.7% for the next.

More news about Lazydays Holdings.

3. LM Funding America (LMFA) – -14.83%

LM Funding America, Inc. operates as a specialty finance company. It provides funding to nonprofit community associations (Associations) primarily located in the state of Florida, as well as in the states of Washington, Colorado, and Illinois. The company offers funding to Associations by purchasing their rights under delinquent accounts that are selected by the Associations arising from unpaid Association assessments. It is also involved in the business of purchasing delinquent accounts on various terms tailored to suit each Association's financial needs, including under its New Neighbor Guaranty program. The company was founded in 2008 and is based in Tampa, Florida.

NASDAQ ended the session with LM Funding America sliding 14.83% to $0.39 on Monday, following the last session’s upward trend. NASDAQ rose 0.27% to $13,018.33, after four sequential sessions in a row of losses, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, LM Funding America has a trailing twelve months EPS of $-2.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -75.84%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 1262.6%, now sitting on 6.72M for the twelve trailing months.

More news about LM Funding America.

4. Sypris Solutions (SYPR) – -9.55%

Sypris Solutions, Inc. engages in the provision of truck components, oil and gas pipeline components, and aerospace and defense electronics primarily in North America and Mexico. It operates in two segments, Sypris Technologies and Sypris Electronics. The Sypris Technologies segment supplies forged, machined, welded, and heat-treated steel components for the commercial vehicle, off highway vehicle, recreational vehicle, automotive, industrial, light truck, and energy markets. This segment also offers drive train components, including axle shafts, transmission shafts, gear sets, steer axle knuckles, and other components for automotive, truck, and recreational vehicle manufacturers. In addition, the segment provides value added operations for drive train assemblies; and manufactures pressurized closures, insulated joints, and other fabricated and specialty products for oil and gas pipelines and related energy markets. The Sypris Electronics segment offers electronic manufacturing services, such as circuit card and full box build manufacturing, high reliability manufacturing, systems assembly and integration, design for manufacturability, and design for specification work for aerospace and defense electronics markets. This segment also provides circuit card assembly services for electronic sensors and systems, including radar systems, tactical ground stations, navigation systems, weapons systems, and targeting and warning systems; and value-added solutions, such as low-volume prototype assembly and high-volume turnkey manufacturing. The company also offers engineering design and repair or inspection services. In addition, it sells its engineered product under the Tube Turns brand. The company was incorporated in 1997 and is headquartered in Louisville, Kentucky.

NASDAQ ended the session with Sypris Solutions falling 9.55% to $1.80 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Sypris Solutions has a trailing twelve months EPS of $-0.09.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -9.83%.

Volume

Today’s last reported volume for Sypris Solutions is 36983 which is 44.02% above its average volume of 25678.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Sypris Solutions’s stock is considered to be overbought (>=80).

More news about Sypris Solutions.

5. Xenetic Biosciences (XBIO) – -9.09%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences falling 9.09% to $3.40 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.75.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.99%.

More news about Xenetic Biosciences.

6. Okta (OKTA) – -8.32%

Okta, Inc. provides identity solutions for enterprises, small and medium-sized businesses, universities, non-profits, and government agencies in the United States and internationally. The company offers Okta's, a suite of products and services is used to manage and secure identities, such as Universal Directory, a cloud-based system of record to store and secure user, application, and device profiles for an organization; Single Sign-On that enables users to access applications in the cloud or on-premise from various devices; Adaptive Multi-Factor Authentication provides a layer of security for cloud, mobile, Web applications, and data; Lifecycle Management that enables IT organizations or developers to manage a user's identity throughout its lifecycle; API Access Management that enables organizations to secure APIs; Access Gateway enables organizations to extend the Workforce Identity Cloud; Advanced Server Access to manage and secure cloud infrastructure; and Okta Identity Governance, an identity access management and identity governance solutions. It also provides Universal Login allows customers to provide login experience across different applications and devices; Attack Protection, a suite of security capabilities that protect from malicious traffics; Adaptive Multi-Factor Authentication that minimizes friction to end users; Passwordless authentication enables users to login without a password and supports in various login methods; Machine to Machine provides standards-based authentication and authorization; Private Cloud that allows customers to run a dedicated cloud instance of Customer Identity Cloud; In addition, the company provides organization; Actions and Extensibility; and Enterprise Connections. It sells its products directly to customers through sales force and channel partners. The company was formerly known as Saasure, Inc. Okta, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

NASDAQ ended the session with Okta falling 8.32% to $69.28 on Monday while NASDAQ rose 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Okta has a trailing twelve months EPS of $-3.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.67%.

More news about Okta.

7. Inovio Pharmaceuticals (INO) – -7.96%

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia, including cervical, vulvar, and anal dysplasia and is under phase II/III clinical trials; INO-3107 for HPV-related recurrent respiratory rapillomatosis and is under Phase 1/2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under phase 1b trial; and INO-4500 vaccine for lassa fever, which is under phase 1b trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

NASDAQ ended the session with Inovio Pharmaceuticals falling 7.96% to $0.43 on Monday while NASDAQ jumped 0.27% to $13,018.33.

Earnings Per Share

As for profitability, Inovio Pharmaceuticals has a trailing twelve months EPS of $-0.63.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.13%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 71.2%, now sitting on 9.62M for the twelve trailing months.

Sales Growth

Inovio Pharmaceuticals’s sales growth is negative 80.6% for the current quarter and 12.9% for the next.

More news about Inovio Pharmaceuticals.

8. Moleculin Biotech (MBRX) – -7.61%

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.

NASDAQ ended the session with Moleculin Biotech falling 7.61% to $0.55 on Monday, following the last session’s downward trend. NASDAQ rose 0.27% to $13,018.33, after four successive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Moleculin Biotech has a trailing twelve months EPS of $-0.98.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -54.9%.

More news about Moleculin Biotech.

9. ImmunoGen (IMGN) – -7.53%

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

NASDAQ ended the session with ImmunoGen sliding 7.53% to $13.09 on Monday, after three successive sessions in a row of losses. NASDAQ rose 0.27% to $13,018.33, after four sequential sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, ImmunoGen has a trailing twelve months EPS of $-0.71.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -49.15%.

Moving Average

ImmunoGen’s value is way below its 50-day moving average of $15.38 and way higher than its 200-day moving average of $11.29.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ImmunoGen’s stock is considered to be overbought (>=80).

Yearly Top and Bottom Value

ImmunoGen’s stock is valued at $13.09 at 17:32 EST, way below its 52-week high of $20.69 and way above its 52-week low of $3.61.

Volatility

ImmunoGen’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.86%, a negative 0.22%, and a positive 2.49%.

ImmunoGen’s highest amplitude of average volatility was 1.48% (last week), 1.96% (last month), and 2.49% (last quarter).

More news about ImmunoGen.

10. Mediaco Holding (MDIA) – -7.14%

MediaCo Holding Inc. owns and operates radio stations in the United States. The company engages in the operation of WQHT-FM and WBLS-FM radio stations in the New York City area. It owns and operates advertising displays, such as bulletins, posters, and digital billboards primarily in Georgia, Alabama, South Carolina, Florida, Kentucky, West Virginia, and Ohio. The company also offers digital advertising and event, which includes sponsorships, ticket sales, licensing, and syndication services. MediaCo Holding Inc. was incorporated in 2019 and is headquartered in New York, New York.

NASDAQ ended the session with Mediaco Holding falling 7.14% to $0.74 on Monday, following the last session’s upward trend. NASDAQ rose 0.27% to $13,018.33, after four successive sessions in a row of losses, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Mediaco Holding has a trailing twelve months EPS of $-0.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -17.9%.

More news about Mediaco Holding.

Stay up to date with our winners and losers daily report